DOC analyst estimates
Healthpeak (DOC) analyst ratings, the average price target and its range, and every firm's latest call.
DOC analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 13, 2026 | Barclays | Healthpeak Properties price target lowered to $21 from $24 at Barclays | $21.00 |
| Oct 13, 2026 | UBS | Healthpeak Properties price target lowered to $20 from $21.50 at UBS | $20.00 |
| Sep 15, 2026 | Jefferies | Healthpeak Properties assumed with a Hold at Jefferies | $21.00 |
| Aug 31, 2026 | Barclays | Healthpeak Properties price target raised to $24 from $23 at Barclays | $24.00 |
| Aug 6, 2026 | Cantor Fitzgerald | Healthpeak Properties price target raised to $23 from $20 at Cantor Fitzgerald | $23.00 |
| Jul 15, 2026 | Wells Fargo | Healthpeak Properties price target raised to $22 from $20 at Wells Fargo | $22.00 |
| Jul 7, 2026 | Barclays | Healthpeak Properties initiated with an Equal Weight at Barclays | $23.00 |
| Jul 6, 2026 | Mizuho Securities | Healthpeak Properties price target raised to $24 from $21 at Mizuho | $24.00 |
| Jun 15, 2026 | BMO Capital | Healthpeak Properties price target raised to $24 from $20 at BMO Capital | $24.00 |
| Jun 11, 2026 | Morgan Stanley | Healthpeak Properties downgraded to Equal Weight at Morgan Stanley | $22.00 |
| May 27, 2026 | Scotiabank | Healthpeak Properties price target raised to $21 from $19 at Scotiabank | $21.00 |
| May 22, 2026 | Morgan Stanley | Healthpeak Properties price target raised to $20 from $18 at Morgan Stanley | $20.00 |
| May 13, 2026 | UBS | Healthpeak Properties price target raised to $19 from $17 at UBS | $19.00 |
| Apr 28, 2026 | Morgan Stanley | Healthpeak Properties price target lowered to $18 from $21 at Morgan Stanley | $18.00 |
| Apr 20, 2026 | UBS | Healthpeak Properties initiated with a Neutral at UBS | $17.00 |
- 17 firms rate DOC: 4 buy, 13 hold, 0 sell.
- The average price target is $22.00 from 9 analysts, from $20.00 to $24.00.
Updated 2026-11-02 23:10 UTC